Patent-litigation settlements agreed by biosimilar sponsors Amgen, Samsung Bioepis and Sandoz that played a part in AbbVie maintaining control over the market for Humira (adalimumab) in the US do not amount to violations of antitrust regulations, a US district court has held.
Illinois district judge Manish Shah dismissed both federal and state claims brought by a class of indirect Humira purchasers, including...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?